1h Free Analyst Time
The plasma fractionation market is forecasted to grow by USD 10.00 bn during 2023-2028, accelerating at a CAGR of 6.09% during the forecast period. The report on the plasma fractionation market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of plasma products treated in respiratory diseases and AATD, a growing list of plasma-derived products, and an increase in M and A for producing plasma-based products.
The plasma fractionation market is segmented as below:
By Product
- Immunoglobulins
- Albumin
- Coagulation factor concentrates
- Protease inhibitors
- Others
By Application
- Immunology
- Neurology
- Hematology
- Critical care
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the plasma fractionation market covers the following areas:
- Plasma fractionation market sizing
- Plasma fractionation market forecast
- Plasma fractionation market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global plasma fractionation market: ADMA Biologics Inc., Bharat Serums and Vaccines Ltd., CSL Ltd., Emergent BioSolutions Inc., GC Biopharma corp. , Grifols SA, Hemarus Plasma, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A, LFB SA, Merck KGaA, Mitsubishi Chemical Group Corp., Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions Netherlands BV, Sanquin, SK Inc., Takeda Pharmaceutical Co. Ltd., and Virchow Laboratories Ltd..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is growing elderly population and related disorders.'
According to the report, one of the major drivers for this market is the growing prevalence of plasma products treated in respiratory diseases and AATD.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ADMA Biologics Inc.
- Bharat Serums and Vaccines Ltd.
- CSL Ltd.
- Emergent BioSolutions Inc.
- GC Biopharma corp.
- Grifols SA
- Hemarus Plasma
- Intas Pharmaceuticals Ltd.
- Kamada Ltd.
- Kedrion S.p.A
- LFB SA
- Merck KGaA
- Mitsubishi Chemical Group Corp.
- Octapharma AG
- PlasmaGen BioSciences Pvt. Ltd.
- Prothya Biosolutions Netherlands BV
- Sanquin
- SK Inc.
- Takeda Pharmaceutical Co. Ltd.
- Virchow Laboratories Ltd.